CRTC-CREB Axis Senses Proteotoxic Stress via Proteasome Inhibition

Study Background and Research Question

The maintenance of protein homeostasis (proteostasis) is vital for cellular health, with the ubiquitin-proteasome system (UPS) playing a central role in degrading misfolded or damaged proteins. Disruption of proteasome activity leads to the accumulation of toxic protein aggregates, a hallmark of aging and neurodegenerative diseases such as Huntington’s disease (HD). While the molecular consequences of proteasome inhibition are well-characterized, the cellular mechanisms that sense and adapt to proteotoxic stress remain incompletely understood.

The reference study investigates how the CRTC-CREB axis functions as a transcriptional sensor in response to proteasome inhibition in Drosophila, aiming to elucidate signaling pathways that allow cells to detect and counteract proteotoxic and oxidative stress. Specifically, the study addresses whether proteasome inhibitors such as MLN2238 can activate CREB-mediated transcription and what downstream consequences this activation has for cellular resilience.

Key Innovation from the Reference Study

The principal innovation lies in the discovery that CRTC-CREB is not merely a passive responder but acts as a sensor and effector for proteotoxic stress induced by proteasome inhibition. The research demonstrates that proteasome inhibitors, including the clinically relevant MLN2238, induce robust CREB activity in vivo through a signaling cascade involving reactive oxygen species (ROS) and c-Jun N-terminal kinase (JNK) activation. This positions the CRTC-CREB axis as a critical node connecting proteasome dysfunction to adaptive gene expression programs, offering a mechanistic bridge between protein quality control, redox signaling, and stress response.

Notably, this work advances the understanding of how transcriptional coactivators such as CRTC and transcription factors like CREB detect and respond to cellular stress, extending beyond traditional views of proteasome inhibition as a purely deleterious event.

Methods and Experimental Design Insights

The study leverages a combination of large-scale compound screening, genetic manipulation, and transcriptomic analysis in Drosophila models. Key methodological elements include:

• Deployment of the U-GLAD (U shape Gum Arabic Liquid Assisted Drug delivery) system to efficiently administer proteasome inhibitors in adult flies, overcoming solubility challenges commonly associated with such compounds.
• Screening of FDA-approved proteasome inhibitors for their ability to activate CREB in vivo, with MLN2238 serving as a potent example of a proteasome β5 subunit inhibitor.
• Assessment of CREB activity using transcriptional reporters and phospho-specific antibodies, both in fly tissues and in human 293T cell lines, to confirm conservation across species.
• Genetic overexpression and loss-of-function approaches to dissect the roles of CRTC and CREB, particularly in tissues vulnerable to proteotoxic stress (e.g., muscle and intestine).
• RNA-seq analysis to profile transcriptional changes upon CRTC overexpression, focusing on genes implicated in redox homeostasis and protein folding.
• Functional assays in a Drosophila Huntington’s disease model to evaluate the impact of CRTC/CREB activation on protein aggregation, motor behavior, and lifespan.

Core Findings and Why They Matter

The study’s central findings provide a compelling narrative linking proteasome inhibition to adaptive transcriptional responses:

• Proteasome inhibition by MLN2238 and related compounds robustly increases CREB activity in adult Drosophila. This effect is dependent on the generation of ROS, which act upstream of JNK signaling.
• JNK activation is both necessary and sufficient for CREB phosphorylation at Ser133 (or its Drosophila equivalent, Ser231), underscoring a conserved signaling axis from proteotoxic stress to transcriptional adaptation.
• Transcriptome profiling reveals that CRTC overexpression upregulates genes involved in redox regulation and proteostasis, supporting a protective role for the CRTC-CREB axis against cellular stress.
• In a fly model of Huntington’s disease, overexpression of CRTC in muscle cells restores protein folding capacity, enhances proteasome activity, reduces pathological protein aggregates, and ameliorates disease phenotypes such as impaired motility and shortened lifespan.
• CREB activity naturally increases during aging, and further boosting its activity suppresses age-associated protein aggregation in muscle, suggesting therapeutic relevance for age-related proteotoxic pathologies.

Together, these findings establish the CRTC/CREB axis as both a sensor and effector of proteotoxic and oxidative stress, with the potential to buffer against the deleterious consequences of impaired proteasome function as shown in the reference study.

Comparison with Existing Internal Articles

Several recent internal resources contextualize the mechanistic insights of this study within broader research workflows focused on proteasome inhibition, oncology, and proteostasis:

• The article "CRTC-CREB Axis Protects Against Proteotoxic Stress via Proteasome Inhibition" emphasizes the conserved role of the CRTC-CREB axis in stress sensing and adaptation, directly paralleling the reference paper’s findings. It further discusses the translational implications for neurodegenerative and aging research, reinforcing the cross-species relevance of these mechanisms.
• Workflow-focused guides such as "MLN2238: Advanced Proteasome β5 Subunit Inhibitor Workflows" and "Advanced Proteasome β5 Subunit Inhibitor Workflows" provide protocol support for researchers employing MLN2238 to dissect chymotrypsin-like proteasome inhibition, model proteotoxic stress, and study drug resistance in multiple myeloma and lymphoma. These articles highlight the importance of precise, reversible inhibition of the β5 subunit and practical troubleshooting strategies, aligning with the experimental needs demonstrated in the reference study.
• The mechanistic review "MLN2238 and the Proteasome-Driven Frontier" integrates findings on the ROS/JNK/CREB axis with oncology-focused research, particularly in bortezomib-resistant malignancies. This resource supports the reference paper’s assertion that ROS and JNK signaling are key mediators of adaptive responses downstream of proteasome inhibition.

Collectively, these internal articles corroborate and extend the reference study’s insights, providing practical frameworks for modeling proteotoxic stress and adaptive signaling in diverse research contexts.

Limitations and Transferability

While the study offers robust evidence for a conserved CRTC-CREB-mediated stress response, several limitations should be considered:

• The primary experimental models are Drosophila and 293T human cell lines. Although key signaling components are conserved, direct extrapolation to mammalian tissue physiology or to human disease contexts (e.g., multiple myeloma, lymphoma) requires further validation.
• The protective effects of CRTC/CREB overexpression are clearly demonstrated in a fly model of Huntington’s disease, but similar benefits in mammalian neurodegeneration or oncology models remain to be directly tested.
• Chemical inhibition of the proteasome triggers a complex network of cellular responses, and the interplay with other stress pathways (e.g., unfolded protein response, NF-κB activation) warrants deeper investigation in future studies.
• Therapeutic manipulation of the CRTC-CREB axis must be approached cautiously, as hyperactivation may have context-dependent effects on cell survival, proliferation, and differentiation.

Despite these caveats, the study provides a compelling framework for the development of new research models and therapeutic strategies targeting proteostasis and stress adaptation mechanisms.

Protocol Parameters

• Compound delivery in Drosophila: Use of the U-GLAD system is recommended to ensure consistent administration of proteasome inhibitors, especially for compounds with solubility challenges.
• Dosing for MLN2238: When modeling chymotrypsin-like proteasome inhibition, begin with nanomolar concentrations based on literature-reported IC50 values (e.g., ~3.4 nM for β5 subunit inhibition as per the product information), and adjust according to species and experimental context.
• ROS/JNK pathway interrogation: Employ genetic or pharmacologic inhibitors of JNK and ROS scavengers to dissect pathway dependencies as in the reference study.
• Transcriptional readouts: Use CREB-responsive luciferase reporters or phospho-CREB immunodetection to monitor axis activation in response to proteasome inhibition.
• Modeling proteotoxic diseases: For neurodegenerative models, overexpress CRTC or activate CREB in relevant tissues and assess protein aggregation, motility, and survival endpoints.

Research Support Resources

For researchers aiming to model proteotoxic or oxidative stress via proteasome inhibition, MLN2238 (SKU A4008) offers a well-characterized, reversible β5 subunit inhibitor suitable for dissecting chymotrypsin-like proteasome activity and adaptive signaling pathways such as CRTC-CREB. MLN2238’s potency and compatibility with workflows targeting multiple myeloma, lymphoma, and drug resistance models are outlined in current protocol guides. For best results, researchers should follow recommended solubility and storage guidelines as detailed by APExBIO.